Risk-guided CKM care through a kidney lens: an architecture for translating risk into action

Cardiovascular-kidney-metabolic (CKM) syndrome describes the clinical convergence of cardiovascular disease, chronic kidney disease (CKD), diabetes, and obesity. Through a kidney lens, CKM care requires more than disease classification; it requires a practical strategy to translate integrated risk assessment into timely and proportional guideline-directed medical therapy (GDMT). We propose a Risk-Guided Therapeutic Architecture for CKM care, represented as a house built from the foundation up. Lifestyle and risk-factor management form the foundation; integrated kidney and cardiovascular risk estimation occupies the first floor; risk-guided pharmacological therapy shapes the second floor; access, affordability, and health-system capacity act as load-bearing walls; and sustained clinical goals constitute the roof. The central innovation is housed on the first floor: proposed implementation thresholds that translate parallel risk assessments into priorities for the pace and intensity of eligible therapy. Rather than proposing another risk score, the architecture uses validated kidney and cardiovascular tools and applies a simple rule: the higher-risk axis governs the pace and intensity of implementing guideline- and phenotype-eligible therapies, rather than expanding pharmacological eligibility itself. These implementation thresholds are author-proposed, hypothesis-generating cut-points intended to synthesize existing evidence and guidelines into a practical framework, rather than new, prospectively validated, or formally guideline-endorsed thresholds in themselves. This framework is intended to complement existing guidelines by helping clinicians move from risk prediction to therapeutic action, reducing inertia while safeguarding individualized care. Because CKM science is still being built, we frame this architecture as a living, testable blueprint intended to evolve along the field’s continuum of learning.